Schistosoma japonicum recombinant Bb (pGEX-Sj32) vaccine induces the dynamic changes of BALB/c mouse splenocyte proliferation, subpopulation and cytokine

  OBJECTIVE: To observe the dynamic changes of the immune response of mouse spleen cells induced by the recombinant Bb vaccine of Schistosoma japonicum and to study its immune mechanism.

   Method: 88 BALB/c mice were randomly divided into oral group and nasal drip group. The oral group mice were vaccinated with 106 clone unit (CFU) recombinant vaccines, and the nasal group mice were injected with nasal drip vaccine. 105 CFU recombinant vaccine; 4 mice in each group were randomly dissected at 2-week intervals within 0-20 weeks after immunization, and spleens were collected to prepare spleen cell suspension, without stimulation (spleen) cell suspension), SjAWA stimulation and ConA stimulate. Nurture. The MTT method is used to detect the proliferation efficiency of spleen cells, and the flow cytometer is used to detect the changes of splenic CD4 + T cells and CD8 + T cell subsets, and the double antibody sandwich ELISA method is used for culture. The expression of TNF-α, IL-10 and IL-12 in the supernatant was detected. Level. Results: Compared with 0 weeks, in the absence of stimulation, SjAWA stimulation or ConA stimulation (2-16 weeks and 2-18 weeks after immunization), the spleen cells of the oral and nasal drip groups were 2-16 and 2 after immunization. Significant proliferation at -18 weeks. P\u003c0.01); the two groups of CD4 + T cell subsets increased significantly in 2-12 weeks after immunization (P\u003c0.01); during the observation period, the CD8 + T cell subsets significantly increased without increasing; Under the culture conditions, the levels of TNF-α, IL-10 and IL-12 in oral splenocytes increased from 2 to 14 weeks, 2 to 18 weeks and 2 to 14 weeks after immunization. It peaked at 8, 10, and 6 weeks. 3 cases increased in 2-14 weeks, 2-18 weeks and 2-18 weeks after immunization, and reached a peak at 8, 10 and 8 weeks.

   Conclusion: Schistosoma japonicum recombinant Bb (pGEX-32) vaccine may trigger an effective immune response in mice.